{"entity":{"id":"pvrig","kind":"target","name":"PVRIG (CD112R)","aka":["CD112R","PVR related immunoglobulin domain containing","C7orf15"],"tldr":"PVRIG is a brake on killer T cells and NK cells that reads CD112 on tumour cells, a cousin of the TIGIT pair. The antibody COM701 blocks it and is being tested in ovarian cancer.","summary":"PVRIG (chromosome 7q22.1) is a cell-surface receptor for NECTIN2 (CD112) that may act as a co-inhibitory receptor suppressing T-cell receptor signals, inhibits T-cell proliferation after NECTIN2 binding and competes with CD226 for it; it is expressed at low levels on freshly isolated T and NK cells, predominantly memory and effector CD8 T cells and both CD16-positive and CD16-negative NK cells, and not on B cells, naive or helper T cells, monocytes or neutrophils (UniProt Q6DKI7). COM701 completed a phase 1/2 study with the TIGIT antibody BMS-986207 and nivolumab (NCT04570839) and is recruiting in relapsed platinum-sensitive ovarian cancer (NCT06888921).","asOf":"2026-09-24","links":[{"label":"HGNC HGNC:32190","url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:32190"},{"label":"UniProt Q6DKI7","url":"https://www.uniprot.org/uniprotkb/Q6DKI7/entry"},{"label":"NCBI Gene 79037","url":"https://www.ncbi.nlm.nih.gov/gene/79037"},{"label":"ClinicalTrials.gov NCT06888921","url":"https://clinicaltrials.gov/study/NCT06888921"}],"tags":["checkpoint-map"],"related":["nectin2","tigit","nivolumab"],"cancers":["ovarian"],"sections":[],"technologies":["checkpoint-inhibitor","tigit-blockade"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":["cancer-immunity-cycle"],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Prevalence not recorded: HGNC and UniProt carry no positivity rates."],"provenance":{"editedBy":"OnCo checkpoint map (HGNC REST, UniProt REST, ClinicalTrials.gov v2)","editedOn":"2026-09-24"},"symbol":"PVRIG","role":["immune-checkpoint"],"sources":[{"label":"HGNC HGNC:32190","url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:32190","note":"approved symbol, name, aliases and cross-references"},{"label":"UniProt Q6DKI7","url":"https://www.uniprot.org/uniprotkb/Q6DKI7/entry","note":"protein name, function and tissue specificity"}],"specificitySources":[],"hgnc":"HGNC:32190","ensembl":"ENSG00000213413","uniprot":"Q6DKI7","entrez":"79037","biology":"An immunoglobulin-domain receptor with an ITIM-like tail; part of the CD226/TIGIT/CD96/PVRIG axis over CD155 and CD112.","whereFound":["Memory and effector CD8 T cells and NK cells (UniProt Q6DKI7)","Ovarian cancer trial of COM701 (NCT06888921)"],"targetClass":"checkpoint","prevalence":[]},"route":"/targets/pvrig/","neighbours":{"target":[{"id":"nectin2","kind":"target","name":"CD112 (nectin-2)","route":"/targets/nectin2/"},{"id":"tigit","kind":"target","name":"TIGIT","route":"/targets/tigit/"}],"drug":[{"id":"nivolumab","kind":"drug","name":"Nivolumab","route":"/drugs/nivolumab/"}],"cancer":[{"id":"ovarian","kind":"cancer","name":"Ovarian cancer","route":"/cancers/ovarian/"}],"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"},{"id":"tigit-blockade","kind":"technology","name":"TIGIT blockade","route":"/technologies/tigit-blockade/"}],"pathway":[{"id":"cancer-immunity-cycle","kind":"pathway","name":"The cancer-immunity cycle","route":"/pathways/cancer-immunity-cycle/"}],"term":[{"id":"checkpoint","kind":"term","name":"Checkpoint (two meanings)","route":"/terms/checkpoint/"}]}}